Musculoskeletal ultrasound is a great tool for monitoring patients’ disease and specifically for visualizing disease damage and subclinical inflammation.
The updated ACR guideline encourages us to reconsider the use of glucocorticoids for patients with RA. Here’s my take.
Consideration of tapering RA therapy is a careful balance between sustained remission and drug tolerability. Here is my take on determining when it is appropriate and which agents to taper.
Clinical trial data to date have shown tofacitinib and baricitinib to be largely similar in efficacy and safety. But are there meaningful differences that might help clinicians choose between them? Here’s my take.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.